Chemotherapy-induced Nausea and Vomiting Drugs

A Global Strategic Business Report

MCP11004


RESEARCH DASHBOARD

  • RELEASE DATE

  • Executive Pool

    3309
  • PRICE

    US$
  • EXPERT INPUTS

    596
  • Companies

    0
  • DATA Tables

    125
  • Pages

    219
  • Edition

    1

WHAT'S BEHIND OUR DATA?

  • DOMAIN TRANSCRIPTS

    140857226
  • BRANDS TRACKED

    6080276
  • FEATURED COMPANIES

    1729341
  • TOPICS COVERED

    22574
  • MARKET SEGMENTS

    82719
  • KEY INDUSTRIES

    91
  • CURATION TEAM

    1574
  • DECISION MAKERS

    4761909

EXECUTIVES TRACKED (368)

  • CXO

    50
  • VICE PRESIDENT

    29
  • DIRECTOR

    132
  • MANAGER

    75
  • MARKETING

    82
EXECUTIVE INSIGHTS
DOMAIN EXPERTS
PLAYERS
PARTICIPANTS
  • EDITION 1
  • TABLES 125
  • REGIONS
  • SEGMENTS
  • PAGES 219
  • US$
  • MCP11004
  • JOIN OUR PANEL

SELECT LICENSE TYPE

Regular

Report Regular Subscription model

Subscription

10 - User Licence. Subcription to 2 yearly updates.

Choose a license to enable Buy Report.

Please select a license type to continue.

  
  

HIGHLIGHTS & REPORT INDEX

SCOPE OF STUDY

The report analyzes the Chemotherapy-induced Nausea and Vomiting Drugs market by the following Segments, and Geographic Regions/Countries:

Segments:
.

Geographic Regions/Countries:
.

SELECT PLAYERS

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Chemotherapy-induced Nausea and Vomiting Drugs – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for 23 Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Global Cancer Incidence Propels Demand for Chemotherapy-Induced Nausea and Vomiting Drugs
Advancements in Anti-Emetic Drug Formulations Drive Adoption of Next-Generation CINV Therapies
Increasing Use of Combination Chemotherapy Spurs Growth in the Anti-Emetic Drug Market
Growing Demand for Oral and Non-Invasive Drug Delivery Systems Generates Opportunities for Innovation
Here`s How Extended-Release and Long-Acting Formulations Sustain Market Growth
Expanding Role of Digital Health Tools in Managing CINV Drives Adoption of Patient-Centered Solutions
Focus on Reducing Hospital Readmissions Due to CINV Strengthens Demand for Effective Treatments
4. GLOBAL MARKET PERSPECTIVE
World Chemotherapy-induced Nausea and Vomiting Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
World Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
World Recent Past, Current & Future Analysis for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
World Historic Review for Serotonin Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
World 15-Year Perspective for Serotonin Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
World Recent Past, Current & Future Analysis for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
World Historic Review for Neurokinin NK1 Receptor Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
World 15-Year Perspective for Neurokinin NK1 Receptor Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
World Recent Past, Current & Future Analysis for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
World Historic Review for Dopamine Antagonist by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
World 15-Year Perspective for Dopamine Antagonist by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
World Recent Past, Current & Future Analysis for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
World Historic Review for Benzodiazepine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
World 15-Year Perspective for Benzodiazepine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
World 15-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
UNITED STATES
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
USA Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
USA Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
USA 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
CANADA
Canada Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Canada Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Canada 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
JAPAN
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
Japan Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Japan Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Japan 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
CHINA
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
China Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
China Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
China 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
EUROPE
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
FRANCE
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
France Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
France Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
France 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
GERMANY
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
Germany Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Germany Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Germany 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
ITALY
Italy Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Italy Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Italy 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
UNITED KINGDOM
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
UK Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
UK Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
UK 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Rest of Europe Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Rest of Europe 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Chemotherapy-induced Nausea and Vomiting Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Asia-Pacific Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Asia-Pacific 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
Rest of World Historic Review for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
Rest of World 15-Year Perspective for Chemotherapy-induced Nausea and Vomiting Drugs by Segment - Percentage Breakdown of Value Sales for Serotonin Receptor Antagonist, Neurokinin NK1 Receptor Antagonist, Dopamine Antagonist, Benzodiazepine and Other Segments for the Years 2015, 2025 & 2030

General queries: [email protected]